Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD
This real-world study evaluated the efficacy of once-daily long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) for improving lung function in patients with chronic obstructive pulmonary disease (COPD). Patients with COPD who were treated with once-da...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/23/7165 |
| _version_ | 1797462863999139840 |
|---|---|
| author | Wei-Chun Huang Chih-Yu Chen Wei-Chih Liao Biing-Ru Wu Wei-Chun Chen Chih-Yen Tu Chia-Hung Chen Wen-Chien Cheng |
| author_facet | Wei-Chun Huang Chih-Yu Chen Wei-Chih Liao Biing-Ru Wu Wei-Chun Chen Chih-Yen Tu Chia-Hung Chen Wen-Chien Cheng |
| author_sort | Wei-Chun Huang |
| collection | DOAJ |
| description | This real-world study evaluated the efficacy of once-daily long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) for improving lung function in patients with chronic obstructive pulmonary disease (COPD). Patients with COPD who were treated with once-daily LABA/LAMA FDCs for 12 months were included. We evaluated their lung function improvement after 12 months of treatment with different LABA/LAMA FDCs. A total of 198 patients with COPD who were treated with once-daily LABA/LAMA FDCs were analyzed. A total of 114 patients were treated with umeclidinium/vilanterol (UMEC/VIL); 34 patients were treated with indacaterol/glycopyrronium (IND/GLY); and 50 patients were treated with tiotropium/olodaterol (TIO/OLO). The forced expiratory volume in 1 s (FEV1) was significantly increased in the patients treated with all three once-daily FDCs (55.2% to 60.9%, <i>p</i> = 0.012 for UMEC/VIL, 58.2% to 63.6%, <i>p</i> = 0.023 for IND/GLY, and 54.1% to 57.7%, <i>p</i> = 0.009 for TIO/OLO). The treatment of COPD patients with TIO/OLO resulted in a significant improvement in both forced vital capacity (FVC%) (71.7% to 77.9%, <i>p</i> = 0.009) and residual volume (RV%) (180.1% to 152.5%, <i>p</i> < 0.01) compared with those treated with UMEC/VIL (FVC%: 75.1% to 81.5%, <i>p</i> < 0.001; RV%:173.8% to 165.2%, <i>p</i> = 0.231) or IND/GLY (FVC%: 73.9% to 79.3%, <i>p</i> = 0.08; RV%:176.8% to 168.3%, <i>p</i> = 0.589). Patients treated with UMEC/VIL or TIO/OLO showed significant improvement in FVC. In addition, those receiving TIO/OLO also showed significant improvement in RV reduction. |
| first_indexed | 2024-03-09T17:43:31Z |
| format | Article |
| id | doaj.art-5b773115f43b4fa4805d5960c35035ae |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T17:43:31Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-5b773115f43b4fa4805d5960c35035ae2023-11-24T11:23:59ZengMDPI AGJournal of Clinical Medicine2077-03832022-12-011123716510.3390/jcm11237165Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPDWei-Chun Huang0Chih-Yu Chen1Wei-Chih Liao2Biing-Ru Wu3Wei-Chun Chen4Chih-Yen Tu5Chia-Hung Chen6Wen-Chien Cheng7Division of Pulmonary and Critical Care, Department of Internal Medicine, China Medical University Hospital, No. 2, Yude Road, North District, Taichung 40402, TaiwanDivision of Pulmonary and Critical Care, Department of Internal Medicine, China Medical University Hospital, No. 2, Yude Road, North District, Taichung 40402, TaiwanDivision of Pulmonary and Critical Care, Department of Internal Medicine, China Medical University Hospital, No. 2, Yude Road, North District, Taichung 40402, TaiwanDivision of Pulmonary and Critical Care, Department of Internal Medicine, China Medical University Hospital, No. 2, Yude Road, North District, Taichung 40402, TaiwanDivision of Pulmonary and Critical Care, Department of Internal Medicine, China Medical University Hospital, No. 2, Yude Road, North District, Taichung 40402, TaiwanDivision of Pulmonary and Critical Care, Department of Internal Medicine, China Medical University Hospital, No. 2, Yude Road, North District, Taichung 40402, TaiwanDivision of Pulmonary and Critical Care, Department of Internal Medicine, China Medical University Hospital, No. 2, Yude Road, North District, Taichung 40402, TaiwanDivision of Pulmonary and Critical Care, Department of Internal Medicine, China Medical University Hospital, No. 2, Yude Road, North District, Taichung 40402, TaiwanThis real-world study evaluated the efficacy of once-daily long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) for improving lung function in patients with chronic obstructive pulmonary disease (COPD). Patients with COPD who were treated with once-daily LABA/LAMA FDCs for 12 months were included. We evaluated their lung function improvement after 12 months of treatment with different LABA/LAMA FDCs. A total of 198 patients with COPD who were treated with once-daily LABA/LAMA FDCs were analyzed. A total of 114 patients were treated with umeclidinium/vilanterol (UMEC/VIL); 34 patients were treated with indacaterol/glycopyrronium (IND/GLY); and 50 patients were treated with tiotropium/olodaterol (TIO/OLO). The forced expiratory volume in 1 s (FEV1) was significantly increased in the patients treated with all three once-daily FDCs (55.2% to 60.9%, <i>p</i> = 0.012 for UMEC/VIL, 58.2% to 63.6%, <i>p</i> = 0.023 for IND/GLY, and 54.1% to 57.7%, <i>p</i> = 0.009 for TIO/OLO). The treatment of COPD patients with TIO/OLO resulted in a significant improvement in both forced vital capacity (FVC%) (71.7% to 77.9%, <i>p</i> = 0.009) and residual volume (RV%) (180.1% to 152.5%, <i>p</i> < 0.01) compared with those treated with UMEC/VIL (FVC%: 75.1% to 81.5%, <i>p</i> < 0.001; RV%:173.8% to 165.2%, <i>p</i> = 0.231) or IND/GLY (FVC%: 73.9% to 79.3%, <i>p</i> = 0.08; RV%:176.8% to 168.3%, <i>p</i> = 0.589). Patients treated with UMEC/VIL or TIO/OLO showed significant improvement in FVC. In addition, those receiving TIO/OLO also showed significant improvement in RV reduction.https://www.mdpi.com/2077-0383/11/23/7165COPDchronic obstructive pulmonary diseaseUMEC/VILumeclidinium/vilanterolIND/GLYindacaterol/glycopyrronium |
| spellingShingle | Wei-Chun Huang Chih-Yu Chen Wei-Chih Liao Biing-Ru Wu Wei-Chun Chen Chih-Yen Tu Chia-Hung Chen Wen-Chien Cheng Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD Journal of Clinical Medicine COPD chronic obstructive pulmonary disease UMEC/VIL umeclidinium/vilanterol IND/GLY indacaterol/glycopyrronium |
| title | Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD |
| title_full | Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD |
| title_fullStr | Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD |
| title_full_unstemmed | Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD |
| title_short | Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD |
| title_sort | differences in pulmonary function improvement after once daily laba lama fixed dose combinations in patients with copd |
| topic | COPD chronic obstructive pulmonary disease UMEC/VIL umeclidinium/vilanterol IND/GLY indacaterol/glycopyrronium |
| url | https://www.mdpi.com/2077-0383/11/23/7165 |
| work_keys_str_mv | AT weichunhuang differencesinpulmonaryfunctionimprovementafteroncedailylabalamafixeddosecombinationsinpatientswithcopd AT chihyuchen differencesinpulmonaryfunctionimprovementafteroncedailylabalamafixeddosecombinationsinpatientswithcopd AT weichihliao differencesinpulmonaryfunctionimprovementafteroncedailylabalamafixeddosecombinationsinpatientswithcopd AT biingruwu differencesinpulmonaryfunctionimprovementafteroncedailylabalamafixeddosecombinationsinpatientswithcopd AT weichunchen differencesinpulmonaryfunctionimprovementafteroncedailylabalamafixeddosecombinationsinpatientswithcopd AT chihyentu differencesinpulmonaryfunctionimprovementafteroncedailylabalamafixeddosecombinationsinpatientswithcopd AT chiahungchen differencesinpulmonaryfunctionimprovementafteroncedailylabalamafixeddosecombinationsinpatientswithcopd AT wenchiencheng differencesinpulmonaryfunctionimprovementafteroncedailylabalamafixeddosecombinationsinpatientswithcopd |